The evidence in the literature so far is inconclusive, and further studies are needed to evaluate the possible role of radiolabeled PSMA PET/CT in thyroid cancer, particularly in TENIS or anaplastic TC patients. This evidence concerns the gene FOLH1 and thyroid gland carcinoma.